应《网络安全法》要求，自2017年10月1日起，未进行实名认证将不得使用互联网跟帖服务。为保障您的帐号能够正常使用，请尽快对帐号进行手机号验证，感谢您的理解与支持！

24小时热门版块排行榜    

小木虫论坛-学术科研互动平台 » 生物医药区 » 新药研发 » 临床研究 » 请教RLD和RS的区别
51/1返回列表
查看: 9032  |  回复: 6
只看楼主 @他人 存档 新回复提醒 (忽略) 收藏    在APP中查看
当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖

星海慧儿

荣誉版主 (职业作家)

木虫精灵

优秀版主优秀版主

[求助] 请教RLD和RS的区别 已有1人参与

在FDA上看到一个产品有RLD也有RS，但是两者不一个厂家，请教RLD和RS到底有何区别，单从字面讲，似乎RS更令人困惑。
MYLAN的是RS，但不是RLD；ASTRA的在橙皮书检索下是RLD，但在drugs@FDA搜索出来的RLD项下又都是NO，很困惑，求解。

请教RLD和RS的区别
1.png


请教RLD和RS的区别-1
2.png
回复此楼

» 猜你喜欢
我是超级天后：天天努力，不落人后！
1楼 2017-02-10 13:51:51
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

孽海情天

木虫 (初入文坛)
请问楼主问题解决了吗?我现在也遇到相同的问题
赞一下 回复此楼
7楼2017-07-03 14:18:58
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
查看全部 7 个回答

mouse103

专家顾问 (著名写手)

【答案】应助回帖

★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
感谢参与，应助指数 +1
星海慧儿: 金币+20, ★★★★★最佳答案, 非常感谢！ 2017-02-10 14:57:38
kk1424: 金币+5 2017-02-10 15:24:33
Reference Listed Drug and Reference Standard

A reference listed drug (21 CFR 314.3(b)) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.  Generally, a reference listed drug is a drug product approved in a new drug application under section 505(c) of the FD&C Act based on full reports of investigations of safety and effectiveness.  A reference standard is the drug product selected by FDA that an applicant seeking approval of an ANDA must use in conducting an in vivo bioequivalence study required for approval.  FDA generally selects a single reference standard that ANDA applicants must use in in vivo bioequivalence testing.  Ordinarily, FDA will select the reference listed drug as the reference standard.  However, in some instances (e.g., where the reference listed drug has been withdrawn from sale and an ANDA is selected as the reference standard), the reference listed drug and the reference standard may be different.

FDA has identified reference listed drugs in the Prescription Drug Product and OTC Drug Product Lists.  Forthcoming, FDA will identify reference listed drugs in the Discontinued Drug Product List.  These identified reference listed drugs represent drug products upon which an applicant can rely in seeking approval of an ANDA.  FDA intends to update periodically the reference listed drugs identified in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists, as appropriate.  

FDA also has identified in the Prescription Drug Product and OTC Drug Product Lists reference standards to which the in vivo bioequivalence is compared.  These identified reference standards represent the FDA’s best judgment at this time as to the appropriate comparator for purposes of in vivo bioequivalence testing.  

In some instances when a listed drug is not designated as a reference listed drug, such listed drug may be shielded from generic competition.  If FDA has not designated a reference listed drug for a drug product the applicant intends to duplicate, the potential applicant may ask FDA to designate a reference listed drug for that drug product.  Potential applicants should consult agency guidance related to referencing approved drug products in ANDA submissions for information on submitting such a request.  If the request is granted, the listed drug will be designated as a reference listed drug, in which case an ANDA citing the designated reference listed drug may be submitted.  Section 1.7, Therapeutic Equivalence Evaluations Codes (products meeting necessary bioequivalence requirements) explains the character coding system (e.g., AB, AB1, AB2, AB3...) for multisource drug products listed under the same heading with two reference listed drugs.

A potential applicant should consult agency guidance related to referencing approved drug products in ANDA submissions for information on submitting a request for selection of a reference standard.  FDA may, on its own initiative, select a new reference standard when doing so will help to ensure that potential applicants have adequate information required for in vivo bioequivalence studies, e.g., in the event that the listed drug currently selected as the reference standard has been withdrawn from sale for other than safety and efficacy reasons.  Historically, there were two situations in which two listed drugs that had been shown to be bioequivalent to each other had both been identified by the symbol “+” in the Orange Book.  The first situation was when the in vivo determination of bioequivalence is self-evident and a waiver of any in vivo bioequivalence may be granted.  The second situation was when the bioequivalence of two listed products may be determined through in vitro methodology.

If an applicant has a question related to the appropriate reference standard, it is recommended that an applicant planning to conduct an in vivo bioequivalence study submit a controlled correspondence to the Office of Generic Drugs.
赞一下(2人) 回复此楼
2楼2017-02-10 14:39:16
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

小朋友681

木虫 (正式写手)
已经在DXY给你回复了
RLD和RS可以相同，也可以不同。RLD是原研的，RS可以是原研，也可以是仿制药，你列举的情况刚好就是这种特例。我看到MOUSE103王老师已经给你找了英文的出处了。
赞一下 回复此楼

» 本帖已获得的红花（最新10朵）

星海慧儿
努力学习！！！加油吧
3楼2017-02-19 22:51:53
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

星海慧儿

荣誉版主 (职业作家)

木虫精灵

优秀版主优秀版主
送红花一朵
引用回帖:
3楼: Originally posted by 小朋友681 at 2017-02-19 22:51:53
已经在DXY给你回复了
RLD和RS可以相同，也可以不同。RLD是原研的，RS可以是原研，也可以是仿制药，你列举的情况刚好就是这种特例。我看到MOUSE103王老师已经给你找了英文的出处了。

嗯，是的。正好我们的是小规格的。谢谢。

发自小木虫Android客户端
赞一下 回复此楼
我是超级天后：天天努力，不落人后！
4楼2017-02-19 23:37:15
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
查看全部 7 个回答
普通表情 龙 兔 虎 猫
信息提示
关闭
请填处理意见
关闭